Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia

Next Previous
Trial Profile

A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jul 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SIILPCV10 (Primary) ; Haemophilus influenzae-pneumococcal vaccine
  • Indications Pneumococcal infections
  • Focus Adverse reactions; Pharmacodynamics; Registrational

Most Recent Events

  • 01 Jun 2021 Primary endpoint (Safety, Tolerability) has been met according to the results published in The Lancet Infectious Diseases
  • 01 Jun 2021 Primary endpoint (Safety, Tolerability) has been met according to the results published in The Lancet Infectious Diseases
  • 01 Jun 2021 Primary endpoint (EPI non-interference) has been met according to the results published in The Lancet Infectious Diseases

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top